Sensus Healthcare, Inc. — 2023 Form 10-K
Business context and reporting period. This filing reports the fiscal year ended December 31, 2023, not standalone fourth-quarter results. Sensus is a medical-device company focused on superficial radiation therapy (SRT) systems and related products and services. It reported one operating segment and 752 installed units across 21 countries at year-end.
Financial performance
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $24.405 million | $44.532 million |
| Gross profit / margin | $14.060 million / 57.6% | $29.628 million / 66.5% |
| Operating income (loss) | $(0.382) million | $14.831 million |
| Net income | $0.485 million | $24.244 million |
| Diluted EPS | $0.03 | $1.46 |
| Cash from operating activities | $(2.145) million | $(1.412) million |
- Revenue fell 45%, primarily due to fewer SRT unit sales as customers deferred purchases amid inflationary pressures. Gross profit declined 52%; management cited lower unit sales and higher vendor costs.
- 2022 results included a $12.779 million gain on the Sculptura asset sale ($15 million cash proceeds). The sale materially elevated 2022 net income and investing cash flow; it did not recur at comparable scale in 2023.
- Operating expenses were $14.442 million, down modestly from $14.797 million. Selling and marketing decreased to $5.608 million; G&A rose to $5.156 million and R&D to $3.678 million.
- Year-end cash and cash equivalents were $23.148 million, down $2.372 million year over year. Current assets were $49.528 million and current liabilities $4.212 million. Inventory increased $8.360 million to $11.861 million, while accounts receivable declined $6.654 million to $10.645 million.
- No revolving-credit borrowings were outstanding at year-end. The Comerica facility provides up to $10 million, secured by company assets, with a $3.5 million minimum unencumbered-liquidity covenant; stated interest is SOFR plus 2.50% when drawn. Total liabilities were $4.868 million.
Outlook, commentary and notable matters
- Management aims to maintain and increase profitability in 2024 through higher sales and expense management while continuing investment in R&D and marketing. It expects 2024 R&D expense to be generally consistent with 2023; no numerical revenue or earnings guidance is provided.
- Management says cash, maturing cash equivalents, available credit and access to capital are sufficient for operating and funding needs for the next 12 months. It identifies revenue generation and gross-margin, expense and earnings fluctuations as factors affecting liquidity.
- In the fourth quarter, the company reversed $853,500 of accrued employee commissions after concluding payment was no longer probable. The reversal reduced 2023 selling and marketing expense and increased EPS by approximately $0.05.
- One U.S. customer generated approximately 61% of 2023 revenue and 85% of year-end receivables; the same customer represented 73% of 2022 revenue. U.S. sales were 91% of 2023 revenue. These concentrations expose results and collections to customer-specific risk.
- The company disclosed an ongoing Department of Justice investigation concerning a physician’s Medicare billing and possible reimbursement-code issues. Sensus says it has cooperated, disputes wrongdoing, and cannot estimate potential costs. Management does not expect ordinary-course legal proceedings in aggregate to materially affect results, position or cash flows.
- Other principal risks include reimbursement changes, dependence on the SRT-100 product line, inflation and international trade issues (including potential impacts in China), supplier concentration, regulation, competition, and cybersecurity. Management reported no cybersecurity incident that materially affected or was reasonably likely to materially affect the company.
- Auditors issued an unqualified opinion on the financial statements and reported no critical audit matters. The auditor did not opine on internal-control effectiveness; management concluded controls were effective. The company is a smaller reporting company and was not required to obtain auditor attestation.
Most important facts for investors to verify
- Whether SRT unit orders and revenue recover after the 2023 decline, and whether gross margin improves from 57.6%.
- How much future revenue and receivables remain concentrated in the largest U.S. customer, and the status and collectability of its balances.
- Inventory levels, turnover and demand conversion, given the $8.360 million year-over-year inventory increase and advance payments to the manufacturer.
- Any developments, potential exposure or cost estimates relating to the DOJ investigation.
- Whether operating cash flow improves and whether liquidity remains adequate without drawing on the secured revolving facility.
- Whether the $853,500 commission-accrual reversal is a one-time estimate change and how results trend excluding that benefit.